News and peer comments about GLP-1 obesity drugs
Recently, we have noted an escalation of newsflow regarding supplier agreements for Novo Nordisk's GLP-1 obesity drug Wegovy from, among others, Ypsomed and Schott Pharma. In its most recent earnings call, peer Gerresheimer also commented that it has contracts with the leading GLP-1 players in place (see image below). The market for GLP-1 obesity drugs has been forecasted reach USD 100bn annual sales within a decade, with Novo Nordisk and Eli Lilly projected to be the market leaders.
Aktuellt
SENASTE
